Adjuvant chemotherapy for bladder cancer-why does level 1 evidence not support it?

Area of Science:

• Oncology
• Urology

Background:

• Neoadjuvant chemotherapy offers significant survival benefits for invasive bladder cancer.
• Current practice patterns often favor cystectomy or adjuvant chemotherapy, despite limited supporting evidence.

Purpose of the Study:

• To highlight the underutilization of neoadjuvant chemotherapy in invasive bladder cancer.
• To emphasize the need for practice pattern changes and further research.

Main Methods:

• Review of existing level 1 evidence regarding neoadjuvant and adjuvant chemotherapy for invasive bladder cancer.
• Comparison of current treatment patterns with evidence-based recommendations.

Main Results:

• Neoadjuvant chemotherapy demonstrated a 5% increase in cure rate and a 3-year increase in median survival.
• Adjuvant chemotherapy lacks robust level 1 evidence and has shown inferior outcomes in some trials.

Conclusions:

• Neoadjuvant chemotherapy should be the standard of care for invasive bladder cancer pending further research.
• A well-designed randomized trial is needed to confirm the utility of adjuvant chemotherapy.